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ABSTRACT
Purpose: Docosahexaenoic acid-paclitaxel is as an inert
prodrug composed of the natural fatty acid DHA covalently
linked to the C2-position of paclitaxel (M. O. Bradley et al.,
Clin. Cancer Res., 7: 3229–3238, 2001). Here, we examined
the role of protein binding as a determinant of the pharma-
cokinetic behavior of DHA-paclitaxel.
Experimental Design: The blood distribution of DHA-
paclitaxel was studied in vitro using equilibrium dialysis and
in 23 cancer patients receiving the drug as a 2-h i.v. infusion
(dose, 200-1100 mg/m2).
Results: In vitro, DHA-paclitaxel was found to bind
extensively to human plasma (99.6  0.057%). The binding
was concentration independent (P  0.63), indicating a non-
specific, nonsaturable process. The fraction of unbound pa-
clitaxel increased from 0.052  0.0018 to 0.055  0.0036
(relative increase, 6.25%; P  0.011) with an increase in
DHA-paclitaxel concentration (0–1000 g/ml), suggesting
weakly competitive drug displacement from protein-binding
sites. The mean ( SD) area under the curve of unbound
paclitaxel increased nonlinearly with dose from 0.089 
0.029 gh/ml (at 660 mg/m2) to 0.624  0.216 gh/ml (at
1100 mg/m2), and was associated with the dose-limiting
neutropenia in a maximum-effect model (R2  0.624). A
comparative analysis indicates that exposure to Cremophor
EL and unbound paclitaxel after DHA-paclitaxel (at 1100
mg/m2) is similar to that achieved with paclitaxel on clini-
cally relevant dose schedules.
Conclusions: Extensive binding to plasma proteins may
explain, in part, the unique pharmacokinetic profile of
DHA-paclitaxel described previously with a small volume of
distribution (4 liters) and slow systemic clearance (0.11
liters/h).
INTRODUCTION
Paclitaxel belongs to the class of taxane diterpenoids (tax-
oids), and contains a C-20 carbon skeleton derived biogeneti-
cally from geranylgeranyol PPi with a unique tricyclopenta-
decane ring system as the core structure. The compound is
highly lipophilic, virtually insoluble in water (0.010 mg/ml),
and is currently formulated for clinical use in a mixed solvent
system containing purified polyoxyethylated castor oil (CrEL)4
and 49.7% (v/v) dehydrated ethanol, USP (1). To increase
aqueous solubility, the design and synthetic preparation of nu-
merous paclitaxel analogues have been described (2). A prodrug
approach would be ideal for this situation, because spontaneous
hydrolysis or enzymatic cleavage of the analogue converts it
back to paclitaxel, and would thus retain the pharmacological
activity associated with the parent drug. Structure-activity rela-
tionships have shown that the hydroxyl moiety at C-2, which is
essential for cytotoxic activity and tubulin polymerization, of-
fers the preferred handle for the synthesis of inert prodrugs (3).
In addition to solving solubility issues, linkage of specific
carriers to paclitaxel offers the possibility of targeted drug
delivery that may enhance the therapeutic index (4). The poten-
tial targeting of paclitaxel to tumor cells has been investigated
with the use of enzyme-activatable prodrugs (5–7) or receptor-
mediated-based approaches (8, 9). Studies have demonstrated
tumoral uptake of some -3 fatty acids from arterial blood (10).
DHA-paclitaxel (Fig. 1), a 2-acyl derivative of the natural fatty
acid DHA and paclitaxel, was shown to be associated with
significantly enhanced tumor distribution and antitumor activity
in various tumor models as compared with paclitaxel after
equitoxic or equimolar doses (11). The clinical preparation of
the prodrug (i.e., Taxoprexin Injection) is administered as a 2-h
infusion in a vehicle that contains 81% less CrEL than Taxol on
a molar basis. In a Phase I study, the disposition of DHA-
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paclitaxel at the recommended dose of 1100 mg/m2 was shown
to be very distinct from that of other known taxanes and char-
acterized by an extremely small volume of distribution (4
liters) and slow systemic clearance (0.11 liters/h; Ref. 12).
Here, we studied the blood distribution of DHA-paclitaxel in
vitro and in vivo in more detail to elucidate the basis for the
unique pharmacokinetic behavior of the drug, and additionally
investigated the relationship between systemic exposure meas-
ures and the dose-limiting toxicity, neutropenia.
MATERIALS AND METHODS
Chemicals and Reagents. Paclitaxel powder (batch,
484034; purity, 98.3%) was kindly provided by Bristol-Myers
Squibb (Woerden, the Netherlands). Separate lots of [G-3H]-
paclitaxel [batch I: specific activity, 8.63 mCi/mg in neat etha-
nol; batch II: specific activity, 22.9 mCi/mg in toluene-ethanol
(98:2)] were provided by Moravek Biochemicals, Inc. (Brea,
CA) and Protarga, Inc. (King of Prussia, PA), respectively.
Ethanolic reference solutions of DHA-paclitaxel (batch,
710303A; 2.1-ml vials containing 100 mg/ml), [3H]DHA-pacli-
taxel (specific activity, 116 Ci/mg), CrEL-P reference material
(batch, 11255666), EPA-paclitaxel, and cephalomannine were
also obtained from Protarga. HSA (fraction V) and AAG (pu-
rified from Cohn fraction VI) were from Sigma Chemical (St.
Louis, MO). Other chemicals were of reagent grade or better.
Human blood was obtained from healthy volunteers, and the
plasma fraction was separated by centrifugation (3000  g for
5 min at 37°C) and used within 1 h after collection. Purified
water was obtained by filtration and deionization using a Milli-
Q-UF system (Millipore, Milford, MA), and was used through-
out.
In Vitro Binding Experiments. Equilibrium dialysis
was performed at 37°C in a humidified atmosphere of 5% CO2
using test cells made from 2.0-ml polypropylene Safe-Lock
vials (Eppendorf, Hamburg, Germany) carrying a 260-l inside
recess in the lids (13). The experiments were carried out with
260-l aliquots of either plasma or protein solution (HSA, 40
mg/ml or AAG, 1.0 mg/ml) containing various concentrations of
DHA-paclitaxel (0, 1, 10, 100, or 1,000 g/ml) in the presence
of a fixed tracer amount of [3H]DHA-paclitaxel, against an
equal volume of PBS. Spectra/Por dialysis tubing with a
12,000–14,000 molecular weight cutoff (Spectrum Medical,
Kitchener, Ontario, Canada) was used as dialysis membrane and
was soaked for 10 min in a PBS solution before use. Preliminary
experiments established that: (a) the time to reach equilibrium
between plasma proteins and the buffer compartment for DHA-
paclitaxel is attained around 20 h, both in the presence and
absence of CrEL-P (data not shown); and (b) the pH (range,
6.2–7.7) had no influence on DHA-paclitaxel binding charac-
teristics (P  0.48; not shown). Hence, experiments were per-
formed using a 24-h dialysis period at pH 7.4. After this time
period, 150-l aliquots of both compartments were transferred
to scintillation vials and mixed with 1.9 ml of Ultima Gold XR
scintillation mixture (Packard Bioscience, Groningen, the Neth-
erlands). After vigorous mixing for 30 s, the radiolabel was
quantified by liquid-scintillation counting using a Model 1409
counter (Wallac Oy, Turku, Finland) until a preset time of 20
min was reached. With the final method, the mean relative SD
in unbound drug fraction of DHA-paclitaxel spiked plasma
samples (1, 10, 100, and 1,000 g/ml) was 15.2%, with values
for within-run and between-run precision ranging from 6.88% to
9.86% and 5.23% to 19.1%, respectively.
The effect of CrEL-P and paclitaxel on binding of DHA-
paclitaxel was evaluated at final concentrations of 0.25 to 10
l/ml and 1.0 g/ml, respectively. Similarly, the influence of
DHA-paclitaxel (1–1000 g/ml) on paclitaxel binding to plasma
was evaluated in the presence and absence of CrEL-P.
All of the experiments were performed in triplicate on four
separate occasions (n  12), except for the HSA and AAG
binding (2 occasions; n  6), and statistical analyses were
carried out using NCSS v5.X (J. L. Hintze, Kayesville, UT). The
effects of DHA-paclitaxel concentration, CrEL-P, and pH on
DHA-paclitaxel binding were estimated by a one-way ANOVA
followed by the Dunnett test. The effects of paclitaxel on DHA-
paclitaxel binding and vice versa was evaluated by a two-tailed
unpaired Student’s t test with equal variances, as recognized by
the F test.
Estimation of Binding Parameters. The drug concen-
tration ratio in the buffer and plasma or protein solution after
dialysis was calculated for each paired observation, and was
taken as an estimate of the unbound drug fraction (fu). The
bound drug fraction (fbd) was calculated as:
fdb  (1 	 fu)  100% (A)
Modified Scatchard plots were constructed using the bound drug
concentration (Cbd) and the unbound drug concentration (Cu),
and initial estimates of binding parameters were obtained using
an automated-model selection procedure implemented in the
Siphar v4.0 software package (InnaPhase, Philadelphia, PA).
The observed data were fitted to the equations for saturable (Eq.
B) and nonsaturable binding (Eq. C):
Cbd  
l1
m

niP  Ki  Cu)/(1  Ki  Cu) (B)
Cbd  (nK)  Cu (C)
where Cbd and Cu are expressed as molar concentrations, m is
the number of binding site classes, n the number of saturable
binding sites per mol of protein in the i-th class (1, 2, or 3), P
the molar concentration of protein, K the association constant,
and nK the contribution constant of nonspecific, nonsaturable
binding on one site. Binding parameters were calculated by an
Fig. 1 Chemical structure of DHA-paclitaxel.
152 Clinical Pharmacokinetics of DHA-Paclitaxel
iterative nonlinear regression analysis, using the Powell mini-
mization algorithm and weighted least squares with a weight
equal to 1/y. The models were evaluated by the Akaike Infor-
mation Criterion, weighted sum of squared deviations and the
coefficient of variation for each parameter.
Patients and Treatment. Thirteen male and 10 female
patients were enrolled into this study; demographic data are
presented in Table 1. Trial design, inclusion and exclusion
criteria, premedication regimens, and detailed clinical profiles
have been documented elsewhere (12). The clinical DHA-pa-
clitaxel preparation (Taxoprexin Injection; Protarga, Inc.) con-
tained 200 mg of the drug formulated in a 5-ml mixture of
CrEL-P and dehydrated ethanol (48:52, v/v), and was addition-
ally diluted in 250 ml of 5% (w/v) dextrose in water. Individual
drug doses were normalized to body-surface area, and admin-
istered once every 3 weeks as a 2-h continuous i.v. infusion
(range, 1.83–4.08 h) using an infusion system with in-line
0.22-m filter at doses ranging from 200 to 1100 mg/m2. The
clinical protocol was approved by the local institutional review
board (The Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins), and all of the patients provided written in-
formed consent before entering the study.
Blood Sampling Procedure. Blood samples were col-
lected in Vacutainer tubes from a peripheral site contralateral to
the infusion site at the following time points: 10 min before
infusion, at the end of infusion, and at 15 and 30 min, 1, 2, 4, 8,
and 24 h after the end of infusion. In 12 patients, additional
samples were obtained at 15 min after the start of infusion, at 48
and 72 h after the end of infusion, and during the first and
second weekly evaluation (approximately days 8 and 15). For
subsequent courses, a trough sample was obtained 10 min before
drug administration and at the end of infusion. Biological sam-
ples were immediately placed in an ice-water bath, centrifuged
within 30 min of collection at 1000  g for 10 min at 4°C, and
were stored at or below 	70°C until analysis.
Measurement of Total Drug in Plasma. Total drug
concentrations of DHA-paclitaxel and paclitaxel in plasma were
determined under Good Laboratory Practice at the Kansas City
Facility of Applied Analytical Industries International (AAII-
KC, Shawnee, KS) by analytical assays based on high-perfor-
mance liquid chromatography with tandem mass spectrometric
detection that were developed and validated by AAII-KC ac-
cording to the Food and Drug Administration guidelines.5 Two
different methods were used to obtain values for DHA-pacli-
taxel plasma concentrations. In the first, DHA-paclitaxel con-
centrations were quantitated in plasma over the range of 5–1,100
g/ml. A different set of calibration standards was prepared for
each Taxoprexin dose level to achieve expected levels of DHA-
paclitaxel and CrEL (14) in patient samples according to the
following scheme: (a) dose level 200 mg/m2: LLOQ, 5.0 g/ml;
ULOQ, 200 g/ml; CrEL-P, 640 g/ml; (b) dose level 400
mg/m2: LLOQ, 10.0 g/ml; ULOQ, 400 g/ml; CrEL-P, 1280
g/ml; (c) 660 mg/m2: LLOQ, 16.5 g/ml; ULOQ, 660 g/ml;
CrEL-P, 2,112 g/ml; (d) 880 mg/m2: LLOQ, 22.0 g/ml;
ULOQ, 880 g/ml; CrEL-P, 2,816 g/ml; and (e) 1,100 mg/m2:
LLOQ, 27.5 g/ml; ULOQ, 1,100 g/ml; CrEL-P, 3,520 g/ml.
Samples with values for DHA-paclitaxel that were LLOQ
from the first assay were then analyzed for both DHA-paclitaxel
and paclitaxel using a second assay with calibration curve
standards over the range of 400–20,000 ng/ml and 10–500
ng/ml, respectively. For the first assay, DHA-paclitaxel and the
internal standard (EPA-paclitaxel) were isolated from 50 to
100-l volumes of plasma using a solvent extraction with ace-
tonitrile and then subjected to chromatography. Separations
were achieved on a Hypersil ODS analytical column (5-m
particle size; 10  2 mm internal diameter; Keystone Scientific,
Inc., Bellefonte, PA), using a nonlinear gradient elution with
methanol:10 mM ammonium acetate (pH 5.5; 25:75, v/v; solvent
A) and neat acetonitrile (solvent B). The solvent program was
set as follows: time 0.01–0.75 min, solvent A:B (35:65); time
1.40–2.50 min, solvent A:B (15:85); time 2.50–2.51 min, sol-
vent A:B (5:95); and time 2.51–2.55 min, solvent A:B (35:65).
Quantitation was achieved by monitoring the product ions (m/z
551.1 for both DHA-paclitaxel and EPA-paclitaxel) of precursor
ions at m/z 1181.6 and m/z 1155.6 for DHA-paclitaxel and
EPA-paclitaxel, respectively.
For the second assay, paclitaxel and the internal standard
(cephalomannine) were extracted from 100-l volumes of
plasma using acetonitrile solvent extraction before chromato-
graphic analysis. The following modified solvent program was
used: time 0.01–0.80 min, solvent A:B (95:5); time 1.40–1.90
min, solvent A:B (15:85); time 2.50–2.51 min, solvent A:B
(5:95); and time 2.51–4.40 min, solvent A:B (95:5). Quantita-
tion was achieved by monitoring the product ions (m/z 568.8 for
paclitaxel, m/z 550.7 for DHA-paclitaxel, and m/z 263.6 for
cephallomannine) of precursor ions at m/z 871.4, m/z 1181.6,
and m/z 832.2 for paclitaxel, DHA-paclitaxel, and cephaloman-
nine, respectively. In all of the cases, the flow rate was set at
0.30 ml/min, and the column effluent was monitored by a
Perkin-Elmer-Sciex API III triple-quadruple mass spectrom-
eter (Woodbridge, Ontario, Canada), using a turbo-ionspray
5 Internet address: http//www.fda.gov/cvm/guidance/published.htm
(May, 2001).
Table 1 Patient demographic data (n  23)
Characteristic Median Range
Baseline screening
Age (years) 62 29–80
Sex (male/female)a 13/10
BSA (m2)b 1.83 1.36–2.66
Height (cm) 170 155–188
Weight (kg) 75 43–90
Pretherapy hematology
Hematocrit (%) 39.2 34.6–40.2
Neutrophils ( 109/liter) 4.43 2.57–12.1
Platelets ( 109/liter) 284 148–589
Pretherapy clinical chemistry
ASAT (IU/L) 28 14–73
ALAT (IU/L) 19 8.0–41
ALP (IU/L) 103 80–2288
Total bilirubin (mg/dl) 0.5 0.3–1.3
Serum creatinine (mg/dl) 0.80 0.60–1.6
Creatinine clearance (ml/min) 103 31.9–169
Serum albumin (mg/ml) 39 33–53
a Data indicate number of patients.
b BSA, body-surface area; ASAT, aspartate aminotransferase;
ALAT, alanine aminotransferase; ALP, alkaline phosphatase.
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source set at 450°C with data collection in a positive polarity
mode.
For both assays, system calibration was accomplished by a
weighted (1/x) linear-regression analysis (correlation coeffi-
cient, 0.996) of the peak area ratio of analyte to internal
standard versus the nominal concentration of the analyte. Ex-
traction recovery ranged between 95.8% and 105.0%, and
96.3% and 104.7% for DHA-paclitaxel and paclitaxel, respec-
tively. The values for precision and accuracy, obtained by
repeated analysis of quality-control samples spiked with the
analytes, ranged between 2.3% and 15.6%, and 86.4% and
114.5%, respectively.
Measurement of DHA-Paclitaxel in Whole Blood. The
analytical procedure for DHA-paclitaxel concentrations in
whole blood samples was based on reversed-phase high-perfor-
mance liquid chromatography with UV detection. Briefly,
200-l aliquots of whole blood were extracted and deprotein-
ized with an equal volume of acetonitrile containing 50 M of
cephalomannine, used as internal standard. Supernatants of the
extract (injection volume, 10 l) were injected directly on an
analytical column packed with Curosil-G material (4 M particle
size; 250  4.6 mm internal diameter; Phenomenex, Torrance,
CA), protected by a Curosil-G Guard Pak (6 M particle size;
30  4.6 mm internal diameter; Phenomenex). The mobile-
phase solvents were composed of water:acetonitrile (99:1, v/v;
solvent A) and acetonitrile (solvent B), and delivered at a flow
rate of 1 ml/min using the following program: time 0.01–5.00
min, solvent A:B (50:50); time 8.0–12.0 min, solvent A:B
(10:90); and time 13.0–16.0 min, solvent A:B (50:50). UV
detection was performed at a wavelength of 230 nm, with
absorbance unit at full scale set at 0.20 from 4 to 10 min, and
absorbance unit at full scale set at 2.0 from 10 to 16 min. The
retention times for the internal standard and DHA-paclitaxel
were 8.90 and 14.3 min, respectively, with an overall chro-
matographic run time of 16 min.
Measurement of Unbound Concentrations. The frac-
tions unbound (fu) DHA-paclitaxel and unbound paclitaxel in
each individual patient plasma sample were determined using
equilibrium dialysis as described previously (13). Biological
samples were analyzed for total radioactivity (i.e., [3H]DHA-
paclitaxel or [3H]paclitaxel) by liquid-scintillation counting as
described above. The unbound drug concentrations (Cu) were
calculated from the fraction unbound drug (fu) and the total drug
concentration (Cp; i.e., the total of unbound, protein bound and
CrEL-P associated), as follows:
Cu  fu  Cp (D)
Measurement of CrEL in Plasma. Analysis of CrEL
concentrations in plasma was performed using an acetonitrile-
n-butyl chloride extraction followed by a colorimetric dye-
binding microassay with Coomassie Brilliant Blue G-250 (Bio-
Rad Laboratories, Munchen, Germany) as described in detail
elsewhere (15). The absorption maximum of the dye at 595 nm
after binding to CrEL and the simultaneous decrease in absorb-
ance at 450 nm were measured within 4 h against a reagent
blank using a Bio-Rad Model 550 automated microplate reader
(Hercules, CA).
Pharmacological Analysis. Estimates of pharmacoki-
netic parameters for unbound DHA-paclitaxel, unbound pacli-
taxel, and CrEL in plasma were derived from individual con-
centration-time data sets by noncompartmental analysis using
the software package WinNonLin v3.0 (Pharsight Corporation,
Mountain View, CA). The peak plasma concentrations and the
time to peak were the observed values. The AUC was calculated
using the linear trapezoidal method from time zero to the time of
the final quantifiable concentration (AUC[tf]). The AUC was
also extrapolated to infinity by dividing the last measured con-
centration by the rate constant of the terminal phase (k), deter-
mined by linear-regression analysis. The systemic clearance was
calculated by dividing the administered dose by the observed
AUC[inf], and the terminal disposition half-life was calculated
as ln (2)/k. The systemic exposure to paclitaxel relative to that
of DHA-paclitaxel was calculated as:
AUC[tf]paclitaxel/AUC[tf]DHA-paclitaxel  100% (E)
after correction for molar differences (molecular weights are
1164 and 854 for DHA-paclitaxel and paclitaxel, respectively).
Estimates of pharmacokinetic parameters for total plasma DHA-
paclitaxel and paclitaxel were calculated previously (12), and
were used to calculate the fraction unbound drug based on the
AUC ratio of unbound to total drug (Cu:Cp). The whole blood:
plasma concentration ratio (Kb/p) of DHA-paclitaxel was de-
fined as:
Kb/p  Cb/Cp (F)
The extent of RBC partitioning (Ke/p) was assessed from the
relationship:
Ke/p  [Kb/p 	 (1 	Hc)]/Hc (G)
with Kb/p depending on hematocrit (Hc) of the whole blood
used in the determination. In this relation, pretherapy values of
Hc were used from each individual. Representative concentra-
tion-time profiles for DHA-paclitaxel in plasma and whole
blood, unbound DHA-paclitaxel, and CrEL were fitted with a
two-compartment model using the software program MW/
Pharm v3.02 (MediWare, Groningen, the Netherlands).
Relationships between exposure to paclitaxel and DHA-
paclitaxel (peak concentration or AUC) and hematological tox-
icity (neutropenia) were explored using nonlinear least squares
regression analysis as implemented in Siphar v4.0. Hematolog-
ical pharmacodynamics were evaluated by analysis of the per-
centage decrease in ANC, calculated as:
% decrease  [(pretherapy value 	 nadir value)/
pretherapy value]  100% (H)
Data were fitted to a sigmoidal maximum-effect model of drug
effect, in which the percentage decrease in ANC (E) is defined
as:
E  E0  Emax [(KP)/(KP50  KP)] (I)
in which E0 is the no-drug effect, Emax is the maximum response
(fixed to a value of 100%), KP is the kinetic parameter of
interest, KP50 is the value of the kinetic parameter predicted to
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result in half of the maximum response, and  is the Hill
constant, describing the sigmoidicity of the curve. Model dis-
crimination was guided by the decrease in the objection function
value (	2 log likelihood), graphical goodness-of-fit analyses,
R2 values, and the Akaike Information Criterion. To differenti-
ate between hierarchical models, P  0.05 was chosen, corre-
sponding to a difference in the OFV of 3.84, with the OFV
approximately 2 distributed.
Statistical Considerations. All of the data are presented
as mean values  SD, unless stated otherwise, and for all of the
tests the a priori cutoff for statistical significance was taken
at 0.05.
RESULTS
In Vitro Binding Interactions. In the absence of
CrEL-P, DHA-paclitaxel was found to bind extensively (99.6 
0.057%) to human plasma proteins, with a free drug fraction of
only 0.0038  0.00057. At clinically relevant concentrations of
DHA-paclitaxel (1–1000 g/ml), this binding was concentration
independent (P  0.63), indicating a nonspecific, nonsaturable
process. In contrast to previous observations with paclitaxel
(16), CrEL-P had only a very minor effect on DHA-paclitaxel
binding, which was only observed at the two highest CrEL-P
concentrations tested (P  0.0001). The free-drug fraction of
DHA-paclitaxel was similar in the absence and presence of
paclitaxel (P  0.19). DHA-paclitaxel binding to normal phys-
iological levels of HSA (99.8  0.051%) and AAG (99.8 
0.037%) was similar to that in plasma, drug-concentration in-
dependent (P  0.13), and not influenced by CrEL-P (P 
0.89). Regression modeling revealed that the binding to HSA
and AAG was nonsaturable on a single site in the concentration
range studied, with the bound concentration linearly related to
unbound drug (R2  0.999; P 0.0056). Binding affinity to both
proteins was identical with an association constant for nonsaturable
binding (nK) to HSA and AAG of 678  22.5 M	1.
In the presence of DHA-paclitaxel, the unbound fraction of
paclitaxel increased from 0.052  0.0018 to 0.055  0.0036
(relative increase, 6.25%; P  0.011) as the DHA-paclitaxel
concentration increased from 0 to 1000 g/ml, suggesting
weakly competitive displacement from protein-binding sites.
This effect was not observed in the absence of CrEL-P (P 
0.65), with unbound paclitaxel fractions of 0.124  0.0071
(DHA-paclitaxel concentration, 0 g/ml) and 0.129  0.0079
(DHA-paclitaxel concentration, 1000 g/ml).
In Vivo Blood Distribution. Concentration-time profiles
of DHA-paclitaxel in whole blood followed the same general
pattern as those in plasma (Fig. 2). At Taxoprexin doses of 880
mg/m2 (n  2) and 1100 mg/m2 (n  6), the DHA-paclitaxel
blood:plasma concentration ratios were 0.486  0.202 and
0.536  0.152, respectively. This suggests that the majority of
DHA-paclitaxel was associated with the plasma fraction, with a
negligible degree of RBC partitioning (Ke/p  	0.113 
0.305; P  0.05 versus Ke/P  0).
Plasma Pharmacokinetics. Plasma pharmacokinetic pa-
rameters at the three highest dose levels are presented in Table
2. Drug concentrations in plasma from patients treated at the two
lowest dose levels (200 mg/m2, n  1; 400 mg/m2, n  2)
remained undetectable beyond 4 h after the end of infusion;
pharmacokinetic parameters for these patients are not listed in
Table 2. Representative plasma concentration-time profiles for
unbound DHA-paclitaxel and paclitaxel are shown in Fig. 3.
Moderate interindividual variability in unbound DHA-paclitaxel
and paclitaxel AUC was noted at the 1100 mg/m2 dose level
Fig. 2 Representative concentration-time profiles of total DHA-pacli-
taxel in plasma (solid symbols) and whole blood (open symbols) in a
patient after Taxoprexin administration at a dose of 1100 mg/m2. Indi-
vidual curves (solid lines) for DHA-paclitaxel concentrations in plasma
and whole blood were fitted with a two-compartment model.
Table 2 Summary of pharmacokinetic parametersa
Parameter
Dose level (mg/m2)
660 (6)b 880 (5)b 1100 (9)b
Unbound DHA-paclitaxel
Cmax (g/ml)c 1.70 0.72 1.60 0.47 1.88 1.16
tf (h) 26.5 1.9 279 241 325 224
AUC[tf] (gh/ml) 17.2 3.6 36.8 23.2 60.2 23.0
AUC[inf] (gh/ml) 26.1 10.7 40.3 19.8 62.9 22.1
T1/2, z (h) 17.8 13.4 57.3 45.0 65.8 35.5
CL (liter/h) 58.2 25.3 55.5 32.9 39.2 15.4
Cu/Cp (%) 0.33 0.071 0.25 0.06 0.27 0.13
Unbound paclitaxel
Cmax (g/ml) 0.013 0.011 0.013 0.005 0.021 0.010
tf (h) 26.5 1.9 53.8 25.6 136 87.7
Tmax (h) 2.14 0.17 2.07 0.32 2.08 0.29
AUC[tf] (gh/ml) 0.089 0.029 0.222 0.122 0.624 0.216
AUC[inf] (gh/ml) 0.225 0.083 0.353 0.094 0.921 0.414
T1/2, z (h) 40.7 22.4 33.2 5.66 80.7 71.2
Cu/Cp (%) 9.7 0.90 8.3 2.9 7.7 1.5
AUC[tf]pac/AUC[tf]DHA
(%)
0.71 0.15 0.91 0.25 1.62 0.88
CrEL
Cmax (l/ml) 2.45 0.41 4.12 0.99 4.86 0.75
tf (h) 23.5 7.5 45.6 27.8 71.0 8.2
AUC[tf] (lh/ml) 31.7 12.6 70.7 42.5 120 30.2
AUC[inf] (lh/ml) 55.2 18.7 108 56.1 162 53.0
T1/2, z (h) 21.8 4.72 35.9 8.01 36.4 10.7
CL (ml/h) 418 95.9 301 177 238 91.2
a Mean values  SD.
b Total number of patients studied at each dose level in parenthesis.
c Cmax, peak plasma concentration; tf, final quantifiable concentra-
tion; Tmax, time to peak plasma concentration; AUC, area under the
plasma concentration-time curve; inf, infinity; T1/2,z, half-life of the
terminal disposition phase; CL, apparent clearance; Cu/Cp, fraction
unbound drug based on the AUC ratio of unbound to total drug; pac,
paclitaxel; DHA, DHA-paclitaxel.
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(i.e.,35%). Exposure to unbound DHA-paclitaxel increased in
near proportional manner with dose (Table 2), and clearance
values were not significantly different between the various dose
levels (P  0.352, Kruskal-Wallis test), suggesting a linear and
dose-independent pharmacokinetic behavior. Consistent with
the in vitro data, 99.7% of drug was bound within the circu-
lation without any trend in time (data not shown).
In vivo formation of paclitaxel was rapid (at 15 min during
the infusion), with peak concentrations observed around the end
of infusion (Table 2; Figs. 3 and 4). However, at the 1100
mg/m2 dose level, unbound paclitaxel represented only 2% of
unbound DHA-paclitaxel exposure. The exposure to unbound
paclitaxel increased in a distinct nonlinear fashion with Taxo-
prexin dose, as a 25% dose increment (from 880 to 1100 mg/m2)
was associated with 70% and 181% increases in peak concen-
tration and AUC[tf], respectively. As a result, systemic exposure
to unbound paclitaxel relative to that of unbound DHA-pacli-
taxel was highly dose-dependent (Table 2), confirming the non-
linear binding process of paclitaxel observed in vitro.
CrEL Pharmacokinetics. Disappearance of CrEL from
the plasma compartment was characterized by elimination in an
apparent biexponential manner (Fig. 4), in line with previous
findings (13). A dose dependence was evident in CrEL clear-
ance (P  0.049, Kruskal-Wallis and Dunn’s tests; Table 2),
which likely relates to inaccurate determination of the terminal
disposition phase at the lower Taxoprexin dose levels resulting
from constraints in assay sensitivity and the sampling scheme.
Exposure-Toxicity Relationships. The parameter esti-
mates for the different pharmacodynamic models, using data
from all 23 of the patients, are summarized in Table 3. Prelim-
inary results demonstrated that separate estimation of the ob-
served maximum effect did not improve the fits, and it was set
to a theoretical maximum value of 100%. The kinetic parame-
ters predicted to result in half of the maximum response showed
a substantial degree of interindividual variability (range, 24–
73%) and were poorly estimated in some models because of the
few patients. With the use of peak concentration as exposure
measure, the fits were significantly worse than those based on
AUC for each individual analyte (OFV 9.34; Fig. 5). The
exposure-neutropenia relationship was best described with the
model based on unbound paclitaxel AUC, although no signifi-
cant improvement of the fit was obtained as compared with total
paclitaxel AUC (OFV  1.48; Table 3).
DISCUSSION
In the present study we have described the in vitro and in
vivo blood distribution of DHA-paclitaxel, a conjugate of the
natural fatty acid DHA and paclitaxel. The binding of DHA-
paclitaxel to human plasma was 99.6% and independent of
drug concentration over the full clinically relevant range. When
binding studies were extended to individual proteins, it was
found that HSA and AAG contributed to about an equal extent
to drug binding, with an association constant for nonspecific,
nonsaturable binding of 678 M	1. This degree of binding is
substantially different from that of paclitaxel, which is 85–87%
bound (17), with overall association constants of 1.7 and 0.082
M	1 for specific and nonspecific binding to HSA (18, 19). The
presence of the long-chain fatty acid linked to the paclitaxel
molecule is the likely explanation for this difference, as fatty
acids are among the most strongly protein-bound endogenous
substrates (association constant 100 M	1; Ref. 20). The
binding to proteins also had a dramatic influence on drug
distribution to RBCs, in line with the small distribution volume
Fig. 3 Representative concentration-time profiles of unbound DHA-
paclitaxel (open symbols) and paclitaxel (closed symbols) in a patient
after Taxoprexin administration at a dose of 1100 mg/m2. Individual
curves (solid lines) for unbound DHA-paclitaxel and paclitaxel concen-
trations in plasma were fitted with a two-compartment model.
Fig. 4 Representative concentration-time profiles of unbound pacli-
taxel (top) and Cremophor EL (bottom) after Taxoprexin administration
at a dose of 1100 mg/m2 (closed symbols) or Taxol at a dose of 175
mg/m2 (open symbols; data from Ref. 22). Individual curves (solid lines)
for unbound paclitaxel and CrEL concentrations after administration of
Taxoprexin or Taxol were fitted with a two-compartment model.
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of DHA-paclitaxel and previous studies of other drugs demon-
strating that RBC partitioning only involves the unbound frac-
tion (21).
It has been shown that CrEL has a major impact on pacli-
taxel binding (16). Although the mechanism underlying this
interaction has not yet been fully elucidated, the presence of
CrEL in solution as large polar micelles is thought to entrap
paclitaxel. In contrast, a decreased fraction of unbound DHA-
paclitaxel in vitro was only observed at CrEL levels measurable
at the highest dose tested clinically (5 l/ml). This is consist-
ent with the dose-dependent peak concentrations of DHA-pacli-
taxel observed here as well as in tumor-bearing mice, wherein
peak levels reached values of 29 and 61 M at doses of 27.4 and
120 mg/kg, respectively (11). Typical for slow clearance drugs,
this phenomenon did not significantly influence overall dispo-
sition profiles, and a linear pharmacokinetic behavior for un-
bound DHA-paclitaxel was found in the tested dose range of
200-1100 mg/m2.
Across all of the dose levels, paclitaxel declined in parallel
with DHA-paclitaxel, suggesting that the elimination rate con-
stant of the prodrug is smaller than that of the metabolite and
that paclitaxel elimination is formation-rate limited. This is
consistent with the 15-fold difference in apparent half-life of
unbound paclitaxel after Taxoprexin Injection (i.e., 80.7 
71.2 h) and Taxol administration (6.12  3.42 h; Ref. 22). At
the recommended doses, 10-fold lower peak concentrations of
unbound paclitaxel were achieved with Taxoprexin administra-
tion (1100 mg/m2) as compared with Taxol (175 mg/m2;
0.021  0.010 versus 0.197  0.099 g/ml), whereas the AUC
values were very similar (0.624  0.216 versus 0.526  0.099
gh/ml; Ref. 22).
The present study demonstrates a striking dose dependence
in unbound paclitaxel pharmacokinetics after Taxoprexin ad-
ministration, with the peak concentration and AUC increasing
2-fold with a 1.25-fold increase in dose (from 880 to 1100
mg/m2). There are many drugs that display nonlinear elimina-
tion kinetics, most commonly resulting from saturable metabolic
pathways (e.g., phenytoin; Ref. 23) or saturable excretion path-
ways (e.g., cyclophosphamide; Ref. 24). However, it is very
unlikely that this also accounts for the nonlinear exposure to
paclitaxel, because: (a) the apparent Michaelis-Menten con-
stants for the principal metabolic route (i.e., paclitaxel 6-
hydroxylation) for human hepatic microsomes (4.0 M) and
complementary expressed CYP2C8 (5.4 M) are 160-fold
higher than concentrations of unbound paclitaxel in patients
(25); and (b) no signs of nonlinearity in paclitaxel tissue distri-
bution and fecal or urinary excretion have been noted after
administration of Taxol (26, 27). Although the mechanistic basis
for the dose-dependent pharmacokinetics of paclitaxel observed
here remains to be elucidated, it is possible that capacity-limited
Table 3 Summary of pharmacodynamic modelinga
Parameter
Paclitaxel DHA-paclitaxel
Unbound Total drug Unbound Total drug
Cmaxa AUC Cmax AUC Cmax AUC Cmax AUC
KP50 0.003  0.001 0.031  0.007 0.044  0.032 0.300  0.215 0.49  0.31 8.61  2.56 190  55 2616  1040
 1.00  0.40 0.77  0.14 1.09  0.44 0.72  0.17 1.10  0.77 1.27  0.39 1.62  0.34 1.10  0.23
E0 0.0001 0.0001 0.036 0.036 0.0004 0.0001 0.0001 0.0001
OFV 119.8 65.56 95.38 67.04 135.5 79.06 77.42 68.08
AIC 103.4 95.96 101.6 97.33 97.91 95.73 98.96 97.53
R2 0.253 0.624 0.465 0.602 0.111 0.548 0.530 0.595
P 0.009 0.0001 0.0006 0.0001 0.14 0.0002 0.0002 0.0001
a Mean values (SD for KP50 and ) from 23 patients using sigmoidal maximum-effect models of exposure-neutropenia relationships.
b Cmax, peak plasma concentration; AUC, area under the plasma concentration-time curve; KP50, kinetic parameter predicted to result in half of
the maximum response expressed in units of g/mL for Cmax and in units of g  h/mL for AUC; , Hill constant; E0, no-drug effect; AIC, Akaike
Information Criterion.
Fig. 5 Percentage decrease in ANC as a function of peak concentration
(Cmax) of unbound paclitaxel (top) and AUC of unbound paclitaxel
(bottom) in 23 patients treated with Taxoprexin DHA-paclitaxel at doses
ranging from 200 to 1100 mg/m2 (E, 200 mg/m2; ‚, 400 mg/m2; ƒ, 660
mg/m2; , 880 mg/m2; and , 1100 mg/m2). The solid lines represent
the fit of a sigmoidal maximum-effect model to the data.
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binding to plasma proteins in the presence of DHA-paclitaxel
contributes to explaining this phenomenon. Support for this
hypothesis comes from in vitro studies indicating that paclitaxel
binding is slightly altered by clinically relevant concentrations
of DHA-paclitaxel as a result of a displacement interaction.
Some clinical implications from this process, particularly with
respect to considerations of treatment schedule, are easily en-
visaged. Most importantly, it makes the use of total paclitaxel
concentrations for therapeutic monitoring misleading, particu-
larly if there is significant interindividual variability in the
apparent binding constant. In addition, changes in proteins lev-
els, which are known to occur in cancer patients, can result in
time dependence of drug kinetics, especially with respect to total
drug (28).
The pharmacodynamic analysis performed here, based on
nonlinear sigmoidal maximum-effect models, revealed signifi-
cant correlations between the percentage decrease in ANC at
nadir and exposure to paclitaxel. The predicted AUC value of
unbound paclitaxel associated with a 50% decrease in ANC
(KP50) was only 0.031 gh/ml after Taxoprexin administration
and 0.790 gh/ml after Taxol in a 3 weekly regimen (17),
despite similar sigmoidicity factors and exposure levels. Al-
though DHA-paclitaxel has no microtubule-assembly activity in
vitro and is thought to be inactive until metabolized (11), the
present results showed a significant relationship between DHA-
paclitaxel exposure and neutropenia. This suggests that the
extended exposure of bone marrow cells to high levels of
DHA-paclitaxel as a result of the small distribution volume can
result in localized toxicity and contribute to the kinetic-dynamic
relationships. The present data did not support, possibly because
of insufficient information, the notion that the unbound concen-
tration should be more closely related to drug effects than total
concentrations. To additionally optimize kinetic-dynamic rela-
tionships, a population analysis for Taxoprexin-induced myelo-
suppression is being performed currently by modeling the entire
time course of neutrophils in each individual patient.6
Previous studies have shown that CrEL clearance increases
with prolonged duration of infusion from 1 to 3 and 24-h, and
that systemic exposure to CrEL depends significantly on the
duration of drug infusion (29). Our current data on CrEL levels
in patients treated with Taxoprexin Injection given as a 2-h
infusion, can therefore not be compared directly with other
infusion schedules. However, it is noteworthy that the mean
CrEL clearance of 302  133 ml/h observed here is consistent
with previous estimates of 199  70.0 ml/h and 361  175 ml/h
after 1-h and 3-h administrations of Taxol, respectively (30).
This provides additional evidence of the time dependence in
CrEL clearance, with disproportional increases in systemic ex-
posure being associated with shortening of infusion duration.
This finding may be of particular importance in view of the
potential role of CrEL in the etiology of acute hypersensitivity
reactions associated with its clinical use. Szebeni et al. (31) have
postulated that an important contributing mechanism to these
hypersensitivity reactions is related to complement activation
because of binding of natural anticholesterol antibodies to the
hydroxyl-rich surface of CrEL micelles. Although only few
episodes of minor acute reactions were observed in the Phase I
study of Taxoprexin Injection (mainly facial flushing graded 1
on the National Cancer Institute common toxicity scale; 2 pa-
tients in cycle 1 and another 5 beyond cycle 1),7 it should be
mentioned that a change in Taxoprexin Infusion duration can
have a much greater impact on complement-activating CrEL
levels at the site of administration and on total CrEL exposure
than would be expected in case of time-independent pharmaco-
kinetics.
It is concluded that DHA-paclitaxel binding to plasma
proteins is an important determinant of its pharmacokinetic
behavior. The major fraction of the administered drug is seques-
tered by HSA and AAG, restricting the unbound concentration,
and affecting distribution and elimination pathways. A compar-
ative analysis indicates that exposure to CrEL and unbound
paclitaxel after Taxoprexin administration at the recommended
dose is similar to that achieved with Taxol on clinically relevant
schedules.
Additional analysis of the disposition of DHA-paclitaxel in
patients, with respect to the current findings, should be of great
importance for our ability to better understand the role of the
various factors that may influence the pharmacologic behavior
and actions of the drug, and of other drugs administered con-
comitantly.
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